Health Care International - ASH Presentation Of A Phase I Study Of REVLIMID(R) And VIDAZA(R) In Higher-Risk MDS Reports Combination Is Well-Tolerated And Has High Activity
Celgene International SÃ rl (NASDAQ: CELG) reported that results of a Phase I study presented today combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well
Comments